and These you was and by hard the a with sites press work other joining us. Juli, Adaptimmune, the clinical year Adaptimmune. our you, collaborators. their summarizing accomplishments colleagues our year. morning, investigators teams dedicated for thank accomplishments We at XXXX for everyone last are release issued here transformative at a of Thank results this
at going I about would our we and providing be spent for to context press forward. strategy Adaptimmune doing because time I better are our the refer details, you think what release
want and with SPEAR beyond our highlights our process co-development including autologous clinical our for opportunity of focus this T-cell decision-making to trials, our faster areas, our So year we and solid key I demonstrating at indications; two, meaningful changes including including to in and our beginning pipeline the efficacy on recent the sarcoma execution partnerships other XXXX new deal tumor organizational the that one, following the announced Astellas, in R&D co-commercialization team market pipeline; in three, and improve in flow which driving ADP-AXMXto collaborations
to our Finally, There and XXXX. component leadership key we changes want future were integration of success. our some accomplishments of manufacturing why touch our is several to on I believe a during
excellent year, former the saw some and testament our but James including leaders build make for that work cancer. people Co-Founder who to the believe team thank Some difference because choose planned we who left And teams. to they a departures Those has can contributed level, work at retired a unexpected, we I including Adaptimmune, do. CEO is with we that at and those want to who executive last teams some notable everyone we Noble to
later fantastic after thank Mike as recent will financing. became John Gavin leadership Firstly, role the in as has was Garone, job, Wood the including announced Last CFO on John's interim moving August, I CEO. our to made will Patient talk in about have the manufacturing I CFO done Supply under the Mike Chief great Lunger be has April. Officer. want we I strides, assume week appointed call. served through a who will in He last and
named We since our was announced In in therapy clear. AFP passion for his has Elliot Elliot to has be very Rafael that former and CMO. R&D pleased announce leaving been was our acting our President that would January, of August Norry that been I Pharmacovigilance and in and Head has of Elliot is and has led cell our CMO. expertise XXXX. permanent program Safety patients and commitment deep Amado, a He
and initial Mark Novartis of early-stage our at and history therapy development formed Mark a changes efficacy. work development worked Kymriah. of our the groups. to cell trials Dudley published on has true with and and is having As other leading is group XX-year early we to and develop their therapies NIH quickly for year, in made in the determine the pioneer a cell field on therapy the late-stage beginning leadership. to announced at and the we clinical we R&D evaluate this safety Notably,
Development Dennis efficacy through named products to as rapidly Williams clear possible. SVP taking registration was Late-Stage as signals with
Phase in and Last these evaluated he products to trial. ADP-AXMX lead has our orphan will affairs soft II continue which substantial designation drug under therapy of for and first regulatory sarcoma ADP-AXMX been for RMAT is The Dennis synovial year Dennis' SPEARHEAD-X team. expertise cell for and leadership, has tissue development sarcomas drug our in regulatory received sarcoma.
range Outside team an and and than biologics broad led by have cell experience research, sciences of since drug groups, with year. Vertex development small Karen therapy early UCB across joining teams. is years pipeline of our us and Miller and and XX more therapy areas. at discovery this we immunologist GSK, late-stage training molecules, translational testing gene has of a our with including last pre-clinical Karen
that T-cells Finally generate most we ultimately advanced cells stem the beyond. Brewer without cell-derived use for team has feeder program. our has ensuring of direct has delivered cell and Jo feats experience stem and of without team one years, can and two need from or allogeneic cell-derived for stromal platform has This are the T-cell our sera the field. decades human up the stem in production allogeneic therapy of produced the led both cell critical clinic and has the platforms Jo many capacity for parameters cells to scale huge the and for allogeneic
team drive the have to the pipeline. that's we So place in
been with product NY-ESO synovial have trials in were to deliver This want trial and X Phase last XXXX. announced in X commercialize ongoing for Phase our aim clinical wholly-owned data These touch time Phase trials X our our us SPEARHEAD-X response leading we in we're escalating GSK first trials. this no with RECIST had dose start to Since reported on and in transitioned then, to have years having our year, responses. to sarcoma, XXXX, assets. our I more to data we doing initial what Now two ADP-AXMX rapidly compelling we
clearly tumor the RECIST basis which other that drug in we products and potency into antitumor our were seeing T-cells could and In range the to our improving development. be we narrowed SPEAR of for the of MAGE-AX indications, convert responses to AFP targeting focus a our to activity, types
As the trial in from first of reported observed previously. tumor RECIST and January months next-generation dosed These the year, SURPASS four we of indications, new trials sub-study. radiation these responses patients in six were this have in approximately began two the
response ADP-AXAFP was target patient determine, develop. are These first responses to we trial patient remarkably dose at we the patients and had indications more in lesions. their durability dosed from will this the and XXX% the target in the trial in which Another data a reduction early need
now a SPEAR However, which with, therapies are of to execute. of and engineering value cancer, our affinity are people the speed proprietary with these T-cell data of for the the importance validation our able we
a of announced start XXXX, which course. trial we we due and we that disclose combination in be study with the will details head will cancer in now have design, will which innovative also neck an confirmed We in
we investors heart keep the cell we of demonstrate solid clinical We of are therapies cusp is everything the do. grateful these revolutionizing for It I people, to trials. of for commitment colleagues the to as patients to The and incredibly us of people in into part get long who company the strength enabled on are for and that we my at will the believe value as the today our tumors. translate the we chosen have to sites where take have clinical benefit
also strike world to On a build beneficial of is to leader to an to to the of way therapy, as a partnerships it's partner cell as access successful accessing our capital U.S. be biotech in necessary both partnerships, alternative although and capital critical source mutual company capabilities. markets a
we based five the years on SPEAR disclosed important alliance in CAR-T T-cells in tumors or beginning we T-cells, Cells, our by acquired our Universal use our first HLA-independent announced on And was that of note HiT with can successful therapies. it this or year, stem pharma which for as to part major the allogeneic At agreement with recently T-cell this building is of cell-derived platform cells our target was Astellas. agreement. program, to allogeneic This Astellas collaboration advances
autologous it's pharma that co-commercialization three, co-development we partnerships; clear T-cell platform; the elements and of our us XX-XX of the assets capital a deal and have non-dilutive sets tone built. our are: capabilities for it's takes to a one, Key SPEAR the derive two, future global our intent beyond that deal and and statement it
investing investment therapy been building more is control we our process of than to what This manufacturing have to broadly is people company. manufacturing capabilities development, supply validates for five partnerships, supply years. any and addition and In cell key and that for becoming in recognized more success
now From the have initiating as the clinical the deliver launched ready. well we cells to be to investment Yard and with point capability facility Navy of of planned standing up for additional existing beginning XXXX, all manufacturing trials as and our at
in are and U.K. to championed the and processes our with new teams how Lunger has clinical greatly the therapies our way Catapult has commercial has the at have vector development Manufacturing in-house. of accomplishments out been full John our in building internal patients. can dedicated to therapy of and is we part These implement space Further the large being manufacturing, integration importance we supply cell and support the optimize he and John enhanced are flexibility. by vector John enable we our This design, facilities built. to in within where to rapidly the we to due test process also working able manufacturing to all trials. team inventory gene Center map
partnerships made have people, and We sizable investments capabilities. in
believe We that as cell integrated will shared of that sold will and vision treatment such by challenges revolutionize a therapy be company. therapy delivering cell the an We have of cancer cell therapy Adaptimmune integrated companies.
cancer. leader bring ground in As this designed with from Adaptimmune people to up is cancer evolution, the cell to therapies a
proof-of-concept on We're study conducting not our here simply technology.
to tumors. to one-product our here to We treat through expertise bring be here here are in XXXX early and to to here innovation a products a cancers. We're with stand We of patients. pipeline broad We're deliver simply five solid different cell not of in responses company. range therapies
the expertise challenges have have of difficult-to-treat the tools we We to cancers. demonstrated tackle and
the leadership throughout data lead privileged and the year updates medical at into lives of phase designing on our and organization transform am with have I therapies. major to to an cell this by and cancer people forward the focused look delivering new conferences. to Adaptimmune entirely we We mission providing
And questions. I with Operator? that, for the call open will
